Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company, announced that the United States Patent and Trademark Office (USPTO) has issued patent claims specific to double-stranded RNAs directed against the important oncology ...
[Published PharmaBiz - Mar 21 2013]